Taysha Gene Therapies, Inc. (TSHA) Investor Relations Documents

Taysha Gene Therapies, Inc. (TSHA) investor relations documents from the company's IR site: 1 presentation, 35 press releases; latest deck 2026-06-21. Read in-app with summaries. First-party data.

June 2026 TSHA-102 Rett Syndrome Program Update Presentation — Taysha Gene Therapies reports 100% response rate in the REVEAL Phase 1/2 trial for TSHA-102, supporting a BLA submission for Rett syndrome.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-11Press releaseTaysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-07Press releaseTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-08-04Press releaseTaysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11
2026-08-03Press releaseTaysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TS
2026-06-25Press releaseTaysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett
2026-06-24Press releaseTaysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
2026-06-24Press releaseTaysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
2026-06-22Press releaseTaysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from
2026-06-21PresentationJune 2026 TSHA-102 Rett Syndrome Program Update Presentation
2026-06-09Press releasePress release
2026-06-06Press releasePress release
2026-06-05Press releaseTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-05-06Press releaseTaysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-01Press releaseTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-04-27Press releasePress release
2026-04-27Press releaseTaysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the A
2026-01-06Press releaseTaysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome
2025-02-26Press releaseTaysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update
2024-11-13Press releaseTaysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update
2024-08-12Press releaseTaysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate Update
2024-05-14Press releaseTaysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update
2024-03-19Press releaseTaysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates
2023-11-14Press releaseTaysha Gene Therapies Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
2023-05-11Press releaseTaysha Gene Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update
2023-03-28Press releaseTaysha Gene Therapies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
2022-11-08Press releaseTaysha Gene Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
2022-08-11Press releaseTaysha Gene Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update
2022-05-16Press releaseTaysha Gene Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update
2022-03-31Press releaseTaysha Gene Therapies Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
2021-11-10Press releaseTaysha Gene Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update
2021-08-16Press releaseTaysha Gene Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update
2021-05-11Press releaseTaysha Gene Therapies Reports First Quarter 2021 Financial Results and Provides a Corporate Update
2021-03-03Press releaseTaysha Gene Therapies Reports Full-Year 2020 Financial Results and Provides a Corporate Update
2020-11-12Press releaseTaysha Gene Therapies Reports Third Quarter 2020 Financial Results and Provides Business Update
Press releaseTaysha Gene Therapies Receives Orphan Drug Designation and Rare Pediatric Disease Designation for TSHA-101 for GM2 Gangl
Press releaseTaysha Gene Therapies Launches with $30 Million Seed Financing and Unrivaled Strategic Partnership with the UT Southwest

TSHA overview · TSHA earnings · TSHA financials · TSHA KPIs · TSHA ownership · TSHA peers · TSHA filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.